- Home
- ACIC vs ERAS Comparison
ACIC vs ERAS Comparison
Compare ACIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 554.5M | 5.5B |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACIC | ERAS |
|---|---|---|
| Price | $10.80 | $11.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 226.1K | ★ 7.8M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | 36.23 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $27.77 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.80 | $1.06 |
| 52 Week High | $13.06 | $24.28 |
Technical Indicators
Market Signals| Indicator | ACIC | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 43.42 |
| Support Level | $10.79 | $9.80 |
| Resistance Level | $11.53 | $16.14 |
| Average True Range (ATR) | 0.46 | 0.69 |
| MACD | -0.00 | 0.23 |
| Stochastic Oscillator | 46.95 | 75.51 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.